A Survey of Neonatal Pharmacokinetic and Pharmacodynamic Studies in Pediatric Drug Development

#	Paper	IF	Citations
29	Clinical research in neonates and infants: Challenges and perspectives. *Pharmacological Research*, **2016**, 108, 80-87	10.2	29
28	Children in clinical trials: towards evidence-based pediatric pharmacotherapy using pharmacokinetic-pharmacodynamic modeling. *Expert Review of Clinical Pharmacology*, **2016**, 9, 1235-44	3.8	18
27	Clinical Utility and Safety of a Model-Based Patient-Tailored Dose of Vancomycin in Neonates. *Antimicrobial Agents and Chemotherapy*, **2016**, 60, 2039-42	5.9	28
26	Antimicrobial dosing in neonates. *Expert Review of Clinical Pharmacology*, **2017**, 10, 239-242	3.8	3
25	Disease burden-research match? Registered trials in child health from low- and middle-income and high-income countries. *Journal of Paediatrics and Child Health*, **2017**, 53, 667-674	1.3	7
24	Challenges and opportunities to enhance global drug development in neonates. *Current Opinion in Pediatrics*, **2017**, 29, 149-152	3.2	7
23	Physiologically Based Pharmacokinetic Prediction of Linezolid and Emtricitabine in Neonates and Infants. *Clinical Pharmacokinetics*, **2017**, 56, 383-394	6.2	14
22	Pharmacokinetics of the anticonvulsant levetiracetam in neonatal foals. *Equine Veterinary Journal*, **2018**, 50, 532-536	2.4	3
21	Pharmacometric Modeling and Simulation Is Essential to Pediatric Clinical Pharmacology. *Journal of Clinical Pharmacology*, **2018**, 58 Suppl 10, S73-S85	2.9	11
20	Dose rationale and pharmacokinetics of dexmedetomidine in mechanically ventilated new-borns: impact of design optimisation. *European Journal of Clinical Pharmacology*, **2019**, 75, 1393-1404	2.8	7
19	Developmental Pharmacodynamics and Modeling in Pediatric Drug Development. *Journal of Clinical Pharmacology*, **2019**, 59 Suppl 1, S87-S94	2.9	7
18	Impact of Regulatory Incentive Programs on the Future of Pediatric Drug Development. *Therapeutic Innovation and Regulatory Science*, **2019**, 53, 609-614	1.2	7
17	Renal Clearance in Newborns and Infants: Predictive Performance of Population-Based Modeling for Drug Development. *Clinical Pharmacology and Therapeutics*, **2019**, 105, 1462-1470	6.1	21
16	Population Pharmacokinetic Analysis and Dose Regimen Optimization in Japanese Infants with an Extremely Low Birth Weight. *Antimicrobial Agents and Chemotherapy*, **2021**, 65,	5.9	0
15	USE OF OFF-LABEL MEDICATIONS IN A NEONATAL INTENSIVE CARE UNIT. *Revista Paulista De Pediatria*, **2021**, 39, e2020063	1.2	1
14	Premature birth: topics in physiology and pharmacological characteristics. *Revista Da Associação Médica Brasileira*, **2021**, 67, 150-155	1.4	0
13	Neonatology. **2021**, 263-269		

12	Physiologically Based Pharmacokinetic Modeling Framework to Predict Neonatal Pharmacokinetics of Transplacentally Acquired Emtricitabine, Dolutegravir, and Raltegravir. *Clinical Pharmacokinetics*, **2021**, 60, 795-809	6.2	3
11	Opioid Treatment for Neonatal Opioid Withdrawal Syndrome: Current Challenges and Future Approaches. *Journal of Clinical Pharmacology*, **2021**, 61, 857-870	2.9	6
10	Clinical pharmacology and dosing regimen optimization of neonatal opioid withdrawal syndrome treatments. *Clinical and Translational Science*, **2021**, 14, 1231-1249	4.9	0
9	Model-Informed Pediatric Drug Development: Application of Pharmacometrics to Define the Right Dose for Children. *Journal of Clinical Pharmacology*, **2021**, 61 Suppl 1, S52-S59	2.9	0
8	Pediatric formulation development - Challenges of today and strategies for tomorrow: Summary report from M-CERSI workshop 2019. *European Journal of Pharmaceutics and Biopharmaceutics*, **2021**, 164, 54-65	5.7	3
7	Drug versus placebo randomized controlled trials in neonates: A review of ClinicalTrials.gov registry. *PLoS ONE*, **2017**, 12, e0171760	3.7	3
6	Neonatal pharmacology and clinical implications. *Drugs in Context*, **2019**, 8, 212608	5.2	8
5	Administración y preparación de antimicrobianos en una unidad chilena de cuidados neonatales. *Enfermería Universitaria*, **2020**, 17,	0.4	
4	Optimal Sample Size for Use in Neonatal Pharmacokinetic Studies.. *Therapeutic Innovation and Regulatory Science*, **2022**, 1	1.2	
3	Bioinformatics and Computer Simulation approaches to the discovery and analysis of Bioactive Peptides.. *Current Pharmaceutical Biotechnology*, **2022**,	2.6	0
2	Gaps in Accessibility of Pediatric Formulations: A Cross-Sectional Observational Study of a Teaching Hospital in Northern Thailand.. *Children*, **2022**, 9,	2.8	1
1	Models for Drug Individualization: Patient to Population Level. **2022**, 303-322		0